DK3467509T3 - Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose - Google Patents

Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose

Info

Publication number
DK3467509T3
DK3467509T3 DK18204837.1T DK18204837T DK3467509T3 DK 3467509 T3 DK3467509 T3 DK 3467509T3 DK 18204837 T DK18204837 T DK 18204837T DK 3467509 T3 DK3467509 T3 DK 3467509T3
Authority
DK
Denmark
Prior art keywords
cell
diagnosis
treatment
specific
multiple sclerosis
Prior art date
Application number
DK18204837.1T
Other languages
English (en)
Inventor
Stefanie Kuerten
Paul V Lehmann
Original Assignee
Cellular Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Tech Ltd filed Critical Cellular Tech Ltd
Application granted granted Critical
Publication of DK3467509T3 publication Critical patent/DK3467509T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/55IL-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/555Interferons [IFN]
    • G01N2333/57IFN-gamma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DK18204837.1T 2011-05-04 2012-05-03 Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose DK3467509T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482365P 2011-05-04 2011-05-04
EP12782351.6A EP2707013B1 (en) 2011-05-04 2012-05-03 Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
DK3467509T3 true DK3467509T3 (da) 2026-02-09

Family

ID=47139471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18204837.1T DK3467509T3 (da) 2011-05-04 2012-05-03 Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose

Country Status (5)

Country Link
US (2) US11340224B2 (da)
EP (2) EP2707013B1 (da)
DK (1) DK3467509T3 (da)
FI (1) FI3467509T3 (da)
WO (1) WO2012154215A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
EP3123176A4 (en) * 2014-03-23 2018-04-25 The Regents of the University of Colorado Diagnosis of multiple sclerosis in human and animal subjects
US10759838B2 (en) * 2015-03-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use
US12458683B2 (en) 2015-03-09 2025-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use
CN109891245B (zh) * 2016-08-12 2023-05-05 美国创新免疫科技有限公司 自身免疫疾病的诊断、预防和/或治疗
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
AU2020284114B2 (en) * 2019-05-31 2025-06-26 Fibrobiologics, Inc. Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN111272998A (zh) * 2020-01-09 2020-06-12 天津天海新域生物科技有限公司 一种同时检测中枢脱髓鞘自身抗体aqp4、mog和mbp的方法
EP4135742A2 (en) 2020-04-17 2023-02-22 Op-T Llc Bioactive peptides and methods of use thereof
CN112362877B (zh) * 2020-10-27 2024-04-12 江苏先声医学诊断有限公司 一种mbp重组蛋白以及其应用
WO2023033903A2 (en) * 2021-08-31 2023-03-09 Cellular Technology Limited Detection of b cell antibody responses in patients with haemophilia and treatment thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013089A1 (en) * 1993-11-10 1995-05-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Compositions and method for stimulating antibody release by b lymphocytes
US20040043431A1 (en) * 2002-08-29 2004-03-04 Aristo Vojdani Diagnosis of multiple sclerosis and other demyelinating diseases
US7598093B2 (en) 2003-07-23 2009-10-06 Ctl Analyzers, Llc Nanoparticle and microparticle based detection of cellular products
AU2005249566B2 (en) 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
CA2577385A1 (en) * 2006-02-07 2007-08-07 Aegera Therapeutics Inc. Method for differentiating between multiple sclerosis subtypes
EP2057998A1 (en) * 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
EP2707013A1 (en) 2014-03-19
EP3467509B1 (en) 2025-11-26
US20140255346A1 (en) 2014-09-11
FI3467509T3 (fi) 2026-02-11
US20190072551A1 (en) 2019-03-07
EP3467509A1 (en) 2019-04-10
US11340224B2 (en) 2022-05-24
EP2707013A4 (en) 2014-11-12
EP2707013B1 (en) 2019-03-20
WO2012154215A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
DK3467509T3 (da) Cns-antigenspecifikke b-celle-, t-celle- og antistofanalyse og deres anvendelse i diagnose og behandling af multipel sklerose
IL288203A (en) Meditopes and meditope-binding antibodies and uses thereof
LTPA2021001I1 (lt) Anti-PD-L1 antikūnai ir jų panaudojimas
EP2769012A4 (en) DAMAGE MECHANISM AND USE METHOD THEREFOR
HUE044591T2 (hu) Anti-CD40 antitestek és alkalmazásuk
HUE037700T2 (hu) OX40-hez kötõdõ ellenanyagok és felhasználásuk
EP2726016A4 (en) DIAGNOSTIC METHOD AND DEVICE
LT2794654T (lt) Anti-phf-tau antikūnai ir jų panaudojimas
BR112014010175A2 (pt) unidades de filtro, componentes e recursos destas e métodos de uso e construção
HUE053545T2 (hu) Humán immundeficiencia vírus semlegesítõ antitestek és eljárások alkalmazásukra
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
EP2561677A4 (en) DEVICE AND CORRESPONDING METHODS
EP2634556A4 (en) SAMPLING DEVICE
DK2580243T3 (da) Antibodies against human cd38
EP2795690A4 (en) ELECTRON TUNING DEVICE AND RELATED METHODS
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
EP2838468A4 (en) INTRAORAL LIGHT THERAPY DEVICES AND METHOD FOR THEIR USE
DK2821415T3 (da) Antistof mod anti-lipoarabinomannan og immunoassay til syrefast bacillær infektion under anvendelse af antistoffet
EP2797561A4 (en) ORAL DEVICES AND USE METHOD
EP2742532A4 (en) DEVICE AND CORRESPONDING METHODS
PT2618835T (pt) Epítopos de célula t e recetores de célula t específicos de antigénio
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
EP3546481C0 (en) ANTI-INTERLEUKIN 22 ANTIBODIES (IL-22) AND THEIR USES
EP2673381A4 (en) BIOSONDES AND METHOD FOR THEIR USE
EP2605053A4 (en) IMAGING DEVICE